Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2001-10-04
2008-08-12
Canella, Karen A (Department: 1643)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C424S093200
Reexamination Certificate
active
07410953
ABSTRACT:
The present invention is to offer a pharmaceutical agent which is capable of suppressing the growth of cancer in cancer cells and the surrounding tissues thereof or in tissue of non-diseased part. An anticancer agent having a mannan-binding protein or gene thereof as an effective component. Examples of a mannan-binding protein are a protein which has an amino acid sequence described in SEQ ID NO:1 of the Sequence Listing and a protein which has an amino acid sequence where one or more amino acid residue(s) is/are subjected to at least one of substitution, deletion, addition and insertion in the amino acid sequence and also has an activity as mannan-binding protein. Examples of a gene are a gene which codes an amino acid sequence described in SEQ ID NO:1 or NO:2 of the Sequence Listing or modified amino acid sequence, or a gene which contains said gene.
REFERENCES:
patent: 5091178 (1992-02-01), Hellstrom et al.
patent: 5270199 (1993-12-01), Ezekowitz
patent: 5951976 (1999-09-01), Segal
patent: WO 89/01519 (1989-02-01), None
patent: WO 92/07579 (1992-05-01), None
patent: WO 94/16716 (1994-08-01), None
patent: WO 99/64453 (1999-12-01), None
Verma et al (Nature, 1997, vol. 389, pp. 239-242).
Eck et al (Gene-Based Therapy, In: the Pharmacological Basis of Therapeutics, Goodman and Gilman, Ed.s, 1996, pp. 77-101).
Orkin et al (AReport and Recommedation of the Panel to Assess the NIH Investment in Research on Gene Therapy @, NIH, 1995).
Schulze et al (Trends in Immunology, 2004, vol. 25, pp. 689-664).
Bodey et al, (Anticancer Research, 2000, vol. 20, pp. 2664-2676).
Vile et al (Gene Therapy, 2000, vol. 7, pp. 2-8).
Addisson et al (PNAS, 1995, vol. 92, pp. 8522-8526).
International Search Report for International Appl. PCT/JP98/039697, Oct. 19, 1998.
International Preliminary Examination Report for PCT/JP98/03697, Aug. 27, 1999.
Fujita T et al., “Mannose-binding Protein Recognizes Glioma Cells:In vitroAnaylsis of Complement Activation on Glioma Cells via the Lectin Pathway,”Jpn. J. Cancer Res.,86:187-192 (Feb. 1995).
Sastry K et al., “The Human Mannose-Binding Protein Gene,”J. Exp. Med.,170:1175-1189 (Oct. 1989).
Kunio , Cationic Liposomes, “Gene Therapy,”Protein, Nucleic Acid, and Enzyme, Special Extra Issue 40(17):2577-2582 (1995). (Japanese language and English translation of Fig. 1).
Makamura K et al.,Molecular Biology of Cells,(2nd ed.), pp. 1031-1036 (1990). (Japanese language with English summary).
Frisch, Christian et al., A Soluble immunoglobin Variable Domain Withoout a Disulfide Bridge: Construction, Accumulation in the Cytoplasm ofE. coli,Purification and Physicochemical Characterization,Biol. Chem. Hopp-Seyler,375:353-356 (May 1994).
Mathews, Christopher K. et al.,Biochemistry,2nd ed., (Menlo Park, CA:The Benjamin/Cummings Publishing Co., Inc., 1996), pp. 165-171.
Kim, Hyun-Won et al., “Restoring Allosterism With Compensatory Mutations in Hemoglobin,”Proc. Natl. Acad. Sci. USA,91:11547-11551 (Nov. 1994).
Kurata, Hiroshi et al., “Structure and Function of Mannan-Binding Proteins Isolated from Human Liver and Serum,”J. Biochem.115:1148-1154 (1994).
Ma, Yong et al., “Functional Expression of Human Mannan-Binding Proteins (MBPs) in Human Hepatoma Cell Lines Infected by Recombinant Vaccinia Virus: Post-Translational Modification, Molecular Assemby, and Differentiation of Serum and Liver MBP,”J. Biochem.122:810-818 (1997).
Kozutsumi, Yasunori et al. “Isolation and Characterization of a Mannan-Building Protein From Rabbit Serum,”Biochemical and Biophysical Research Communications,95:658-664 (Jul. 31, 1980).
Neurath, Hans, ed.,Perspectives in Biochemistry,vol. 1 (Washington:American Chemical Society, 1989), pp. 6-9.
Garred P., et al., “Increased Frequency of Homozygosity of Abnormal Mannan-Binding-Protein Alleles in Patients with Suspects Immunodeficiency,”The Lancet,vol. 346, pp. 941-943 (Oct. 7, 1995).
Ohta M., et al., “Complement-Dependent Cytotoxic Activity of Serum Mannan-Binding Protein Towards Mammalian Cells with Surface-Exposed High-Mannose Type Glycans,”Medline, Glycoconjugate Journal,vol. 11, pp. 304-308 (Aug. 1994).
Wawotzny, R., et al., “Are Matrix-Immobilized Neoglyocproteins, Plant and Human Lectins and Carbohydrate-Binding Anitbodies from Human Serum Mediators of Adhesion in Vitro for Carcinoma and Lymphosarcoma Cells?”Biosis, Anticancer Research,vol. 15, pp. 169-174 (1995).
Sabine, A., “Evidence for the Involvement of Serum Lectins and Carbohydrate-Binding Antibodies in Tumor Defence,”Anticancer Research,vol. 15, p. 1816 (1995).
Ma Yong, et al., “Antitumor activity of Mannan-Binding Protein In Vivo as Revealed by a Virus Expression System: Mannan-Binding Protein-Dependent Cell-Mediated Cytotoxicity,”Proceeding of the National Academy of Sciences of the United States of America,vol. 96, pp. 371-375 (Jan. 1999).
Canella Karen A
Kolisch & Hartwell, P.C.
Takara Bio Inc.
LandOfFree
Anticancer agent does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Anticancer agent, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anticancer agent will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3994223